Sclerosing cholangitis in the era of target chemotherapy: a possible anti-VEGF effect.

@article{Delis2009SclerosingCI,
  title={Sclerosing cholangitis in the era of target chemotherapy: a possible anti-VEGF effect.},
  author={Spiros G. Delis and Charicleia Triantopoulou and Andreas Bakoyiannis and Nikolaos C Tassopoulos and Kostas Athanasiou and Christos G Dervenis},
  journal={Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
  year={2009},
  volume={41 1},
  pages={72-7}
}
Preoperative systemic chemotherapy is generally applied in patients who undergo hepatic resection for colorectal metastases. Although the tumour response rate has been improved recently with the development of new molecular targeted therapies the related hepatic injury is ill defined. Bevacizumab is a monoclonal antibody to vascular endothelial growth factor. It can achieve high response rates and is accepted as a first line treatment in the metastatic colorectal disease. However, the data… CONTINUE READING